Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins

Journal of Immunology

Volumn 186, Issue 8, 2011, Pages 4881-4894

  Ray, Tathagat Dutta ^a,b   Lewis, Lisa A ^a   Gulati, Sunita ^a   Rice, Peter A ^a   Ram, Sanjay ^a,c  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c Lazare Research Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY H8; BLOCKING ANTIBODY; GLYCOPEPTIDASE; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; LIPOPROTEIN; LIPOPROTEIN LAZ; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY; PENTAPEPTIDE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; GENE DELETION; GLYCOSYLATION; HOST RESISTANCE; HUMAN; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PENTAPEPTIDE REPEAT MOTIF; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TARGETING; SEQUENCE ANALYSIS; SERUM BACTERICIDAL ACTIVITY;

AMINO ACID SEQUENCE; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; BACTERIAL OUTER MEMBRANE PROTEINS; BLOOD BACTERICIDAL ACTIVITY; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; MICROBIAL VIABILITY; MOLECULAR SEQUENCE DATA; MUTATION; NEISSERIA MENINGITIDIS; OLIGOPEPTIDES; PROTEIN BINDING;

EID: 79955047680     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003623     Document Type: Article

References (74)

1. Baker, M. G., D. R. Martin, C. E. Kieft, and D. Lennon. 2001. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J. Paediatr. Child Health 37: S13-S19. (Pubitemid 32989606)
2. Martin, D. R., S. J. Walker, M. G. Baker, and D. R. Lennon. 1998. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4: P1.4. J. Infect. Dis. 177:497-500. (Pubitemid 28063785)
3. Rosenstein, N. E., B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes. 2001. Meningococcal disease. N. Engl. J. Med. 344:1378-1388.
4. Sacchi, C. T., L. L. Pessoa, S. R. Ramos, L. G. Milagres, M. C. Camargo, N. T. Hidalgo, C. E. Melles, D. A. Caugant, and C. E. Frasch. 1992. Ongoing group B Neisseria meningitidis epidemic in São Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex. J. Clin. Microbiol. 30:1734-1738.
5. Cartwright, K. A., J. M. Stuart, D. M. Jones, and N. D. Noah. 1987. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol. Infect. 99:591-601. (Pubitemid 18034332)
6. Trotter, C. L., N. J. Gay, and W. J. Edmunds. 2006. The natural history of meningococcal carriage and disease. Epidemiol. Infect. 134:556-566.
7. Christensen, H., M. May, L. Bowen, M. Hickman, and C. L. Trotter. 2010. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10:853-861.
8. Schwartz, B., P. S. Moore, and C. V. Broome. 1989. Global epidemiology of meningococcal disease. Clin. Microbiol. Rev. 2 (Suppl): S118-S124.
9. Rosenstein, N. E., B. A. Perkins, D. S. Stephens, L. Lefkowitz, M. L. Cartter, R. Danila, P. Cieslak, K. A. Shutt, T. Popovic, A. Schuchat, et al. 1999. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 180:1894-1901.
10. Jordens, J. Z., J. N. Williams, G. R. Jones, M. Christodoulides, and J. E. Heckels. 2004. Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students. Infect. Immun. 72:6503-6510. (Pubitemid 39425431)
11. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:1327-1348.
12. Griffiss, J. M., and D. K. Goroff. 1983. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J. Immunol. 130:2882-2885. (Pubitemid 13107724)
13. Jarvis, G. A., and J. M. Griffiss. 1991. Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule. J. Immunol. 147:1962-1967.
14. Rice, P. A., H. E. Vayo, M. R. Tam, and M. S. Blake. 1986. Immunoglobulin G antibodies directed against protein III block killing of serum-resistant Neisseria gonorrhoeae by immune serum. J. Exp. Med. 164:1735-1748. (Pubitemid 17184201)
15. Frasch, C., W. Zollinger, and J. Poolman. 1985. Proposed schema for identification of serotypes of Neisseria meningitidis. In The Pathogenic Neisseria. G. Schoolnik, ed. American Society for Microbioogy, Washington, D. C., p. 519-524.
16. Tettelin, H., N. J. Saunders, J. Heidelberg, A. C. Jeffries, K. E. Nelson, J. A. Eisen, K. A. Ketchum, D. W. Hood, J. F. Peden, R. J. Dodson, et al. 2000. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287:1809-1815. (Pubitemid 30143964)
17. Moe, G. R., S. Tan, and D. M. Granoff. 1999. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect. Immun. 67:5664-5675. (Pubitemid 29508084)
18. Madico, G., J. A. Welsch, L. A. Lewis, A. McNaughton, D. H. Perlman, C. E. Costello, J. Ngampasutadol, U. Vogel, D. M. Granoff, and S. Ram. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510. (Pubitemid 43939163)
19. Welsch, J. A., S. Ram, O. Koeberling, and D. M. Granoff. 2008. Complementdependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197:1053-1061. (Pubitemid 351590035)
20. Welsch, J. A., R. Rossi, M. Comanducci, and D. M. Granoff. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol. 172:5606-5615. (Pubitemid 38542063)
21. Granoff, D. M., A. Bartoloni, S. Ricci, E. Gallo, D. Rosa, N. Ravenscroft, V. Guarnieri, R. C. Seid, A. Shan, W. R. Usinger, et al. 1998. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J. Immunol. 160:5028-5036. (Pubitemid 28215339)
22. Hou, V. C., G. R. Moe, Z. Raad, T. Wuorimaa, and D. M. Granoff. 2003. Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect. Immun. 71:6844-6849. (Pubitemid 37475313)
23. Apicella, M. A., R. E. Mandrell, M. Shero, M. E. Wilson, J. M. Griffiss, G. F. Brooks, C. Lammel, J. F. Breen, and P. A. Rice. 1990. Modification by sialic acid of Neisseria gonorrhoeae lipooligosaccharide epitope expression in human urethral exudates: an immunoelectron microscopic analysis. J. Infect. Dis. 162:506-512. (Pubitemid 20239971)
24. Lewis, L. A., J. Ngampasutadol, R. Wallace, J. E. Reid, U. Vogel, and S. Ram. 2010. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 6: e1001027.
25. Giuliani, M. M., L. Santini, B. Brunelli, A. Biolchi, B. Aricò, F. Di Marcello, E. Cartocci, M. Comanducci, V. Masignani, L. Lozzi, et al. 2005. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect. Immun. 73:1151-1160. (Pubitemid 40165775)
26. Ram, S., A. D. Cox, J. C. Wright, U. Vogel, S. Getzlaff, R. Boden, J. Li, J. S. Plested, S. Meri, S. Gulati, et al. 2003. Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J. Biol. Chem. 278:50853-50862. (Pubitemid 38020315)
27. Fisette, P. L., S. Ram, J. M. Andersen, W. Guo, and R. R. Ingalls. 2003. The lip lipoprotein from Neisseria gonorrhoeae stimulates cytokine release and NF-κB activation in epithelial cells in a Toll-like receptor 2-dependent manner. J. Biol. Chem. 278:46252-46260. (Pubitemid 37452195)
28. Ram, S., A. K. Sharma, S. D. Simpson, S. Gulati, D. P. McQuillen, M. K. Pangburn, and P. A. Rice. 1998. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J. Exp. Med. 187:743-752. (Pubitemid 28115190)
29. Virji, M., and J. E. Heckels. 1988. Nonbactericidal antibodies against Neisseria gonorrhoeae: evaluation of their blocking effect on bactericidal antibodies directed against outer membrane antigens. J. Gen. Microbiol. 134:2703-2711.
30. Masignani, V., R. Rappuoli, and M. Pizza. 2002. Reverse vaccinology: a genome-based approach for vaccine development. Expert Opin. Biol. Ther. 2:895-905. (Pubitemid 36033255)
31. Fletcher, L. D., L. Bernfield, V. Barniak, J. E. Farley, A. Howell, M. Knauf, P. Ooi, R. P. Smith, P. Weise, M. Wetherell, et al. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088-2100. (Pubitemid 38419922)
32. Hou, V. C., O. Koeberling, J. A. Welsch, and D. M. Granoff. 2005. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J. Infect. Dis. 192:580-590. (Pubitemid 41099306)
33. Masignani, V., M. Comanducci, M. M. Giuliani, S. Bambini, J. Adu-Bobie, B. Arico, B. Brunelli, A. Pieri, L. Santini, S. Savino, et al. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799. (Pubitemid 36350873)
34. Taha, M. K., M. L. Zarantonelli, J. M. Alonso, L. M. Naess, J. Holst, B. Feiring, and E. Rosenqvist. 2007. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine 25:2537-2538. (Pubitemid 46400920)
35. Williams, J. N., P. J. Skipp, C. D. O'Connor, M. Christodoulides, and J. E. Heckels. 2009. Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect. Immun. 77:5080-5089.
36. Bhattacharjee, A. K., E. E. Moran, J. S. Ray, and W. D. Zollinger. 1988. Purification and characterization of H.8 antigen from group B Neisseria meningitidis. Infect. Immun. 56:773-778. (Pubitemid 18092131)
37. Cannon, J. G. 1989. Conserved lipoproteins of pathogenic Neisseria species bearing the H.8 epitope: lipid-modified azurin and H.8 outer membrane protein. Clin. Microbiol. Rev. 2 (Suppl): S1-S4.
38. Woods, J. P., S. M. Spinola, S. M. Strobel, and J. G. Cannon. 1989. Conserved lipoprotein H.8 of pathogenic Neisseria consists entirely of pentapeptide repeats. Mol. Microbiol. 3:43-48. (Pubitemid 19239956)
39. Ryden, L., and J. Lundgren. 1976. Homology relationships among the small blue proteins. Nature 261:344-346.
40. Joiner, K. A., R. Scales, K. A. Warren, M. M. Frank, and P. A. Rice. 1985. Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. J. Clin. Invest. 76:1765-1772. (Pubitemid 16196043)
41. Schroeder, H. W., Jr., and L. Cavacini. 2010. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125 (2 Suppl 2): S41-S52.
42. Raju, T. S., J. B. Briggs, S. M. Borge, and A. J. Jones. 2000. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10:477-486. (Pubitemid 30216089)
43. Wright, A., and S. L. Morrison. 1997. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol. 15:26-32. (Pubitemid 27067150)
44. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
45. Thomas, L., and J. H. Dingle. 1943. Investigations of meningococcal infection. III. The bactericidal action of normal and immune sera for the meningococcus. J. Clin. Invest. 22:375-385.
46. Joseph, B., M. Dondrup, R. Schwarz, H. Neuweger, S. Jaenicke, A. Goesmann, S. Schneiker-Bekel, A. Becker, M. Frosch, and C. Schoen. 2010. Differential genome expression of serogroup B meningococci under in vivo mimicking conditions. In 17th International Pathogenic Neisseria Conference, Vol. 48. Banff, AB, Canada, p. 48.
47. Wu, H. J., K. L. Seib, J. L. Edwards, M. A. Apicella, A. G. McEwan, and M. P. Jennings. 2005. Azurin of pathogenic Neisseria spp. is involved in defense against hydrogen peroxide and survival within cervical epithelial cells. Infect. Immun. 73:8444-8448. (Pubitemid 41740341)
48. Holst, J., D. Martin, R. Arnold, C. C. Huergo, P. Oster, J. O'Hallahan, and E. Rosenqvist. 2009. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(Suppl 2):B3-B12.
49. Bjune, G., E. A. Høiby, J. K. Grønnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nøkleby, E. Rosenqvist, et al. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
50. Borrow, R., P. Balmer, and E. Miller. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23:2222-2227. (Pubitemid 40341456)
51. Koeberling, O., J. A. Welsch, and D. M. Granoff. 2007. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine 25:1912-1920. (Pubitemid 46176316)
52. O'Hallahan, J., D. Lennon, P. Oster, R. Lane, S. Reid, K. Mulholland, J. Stewart, L. Penney, T. Percival, and D. Martin. 2005. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 23:2197-2201. (Pubitemid 40341450)
53. Snape, M. D., T. Dawson, P. Oster, A. Evans, T. M. John, B. Ohene-Kena, J. Findlow, L. M. Yu, R. Borrow, E. Ypma, et al. 2010. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29: e71-e79.
54. Wedege, E., E. A. Høiby, E. Rosenqvist, and G. Bjune. 1998. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66:3223-3231. (Pubitemid 28303120)
55. Wedege, E., B. Kuipers, K. Bolstad, H. van Dijken, L. O. Frøholm, C. Vermont, D. A. Caugant, and G. van den Dobbelsteen. 2003. Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine. Infect. Immun. 71:3775-3781. (Pubitemid 36753698)
56. Blake, M. S., L. M. Wetzler, E. C. Gotschlich, and P. A. Rice. 1989. Protein III: structure, function, and genetics. Clin. Microbiol. Rev. 2 (Suppl): S60-S63.
57. Munkley, A., C. R. Tinsley, M. Virji, and J. E. Heckels. 1991. Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein. Microb. Pathog. 11:447-452.
58. Rosenqvist, E., A. Musacchio, A. Aase, E. A. Høiby, E. Namork, J. Kolberg, E. Wedege, A. Delvig, R. Dalseg, T. E. Michaelsen, and J. Tommassen. 1999. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infect. Immun. 67:1267-1276. (Pubitemid 29108504)
59. Joiner, K. A., K. A. Warren, E. J. Brown, J. Swanson, and M. M. Frank. 1983. Studies on the mechanism of bacterial resistance to complement-mediated killing. IV. C5b-9 forms high molecular weight complexes with bacterial outer membrane constituents on serum-resistant but not on serum-sensitive Neisseria gonorrhoeae. J. Immunol. 131:1443-1451. (Pubitemid 13048904)
60. Joiner, K. A., K. A. Warren, C. Hammer, and M. M. Frank. 1985. Bactericidal but not nonbactericidal C5b-9 is associated with distinctive outer membrane proteins in Neisseria gonorrhoeae. J. Immunol. 134:1920-1925. (Pubitemid 15128961)
61. Pfeiffer, F., and R. Issaeff. 1894. Uber die Specifishche der Bedeutung der Choleraimmunitat. Z. Hyg. Infektionskr. 17:355-400.
62. Neisser, M., and F. Wechsberg. 1901. Ueber die Wirkungsart Bactericider Sera. Munch. Medi. Wochenschr. 697.
63. Selander, B., H. Käyhty, E. Wedege, E. Holmström, L. Truedsson, C. Söderström, and A. G. Sjöholm. 2000. Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG. J. Clin. Immunol. 20:138-149. (Pubitemid 30314318)
64. Hall, W. H., R. E. Manion, and H. H. Zinneman. 1971. Blocking serum lysis of Brucella abortusby hyperimmune rabbit immunoglubulin A. J. Immunol. 107:41-46.
65. Glenchur, H., W. H. Hall, and H. H. Zinneman. 1959. Blocking antibodies in rabbits infected with Brucella melitensis. Proc. Soc. Exp. Biol. Med. 101:422-425.
66. Guttman, R. M., and B. A. Waisbren. 1975. Bacterial blocking activity of specific IgG in chronic Pseudomonas aeruginosa infection. Clin. Exp. Immunol. 19:121-130.
67. Waisbren, B. A., and I. Brown. 1966. A factor in the serum of patients with persisting infection that inhibits the bactericidal activity of normal serum against the organism that is causing the infection. J. Immunol. 97:431-437.
68. MacLennan, C. A., J. J. Gilchrist, M. A. Gordon, A. F. Cunningham, M. Cobbold, M. Goodall, R. A. Kingsley, J. J. van Oosterhout, C. L. Msefula, W. L. Mandala, et al. 2010. Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science 328:508-512.
69. Leatherbarrow, R. J., T. W. Rademacher, R. A. Dwek, J. M. Woof, A. Clark, D. R. Burton, N. Richardson, and A. Feinstein. 1985. Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Mol. Immunol. 22:407-415. (Pubitemid 15071616)
70. Raju, T. S. 2008. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 20:471-478.
71. Tao, M. H., and S. L. Morrison. 1989. Studies of aglycosylated chimeric mousehuman IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143:2595-2601. (Pubitemid 19260070)
72. Mimura, Y., R. Ghirlando, P. Sondermann, J. Lund, and R. Jefferis. 2001. The molecular specificity of IgG-Fc interactions with Fc gamma receptors. Adv. Exp. Med. Biol. 495:49-53. (Pubitemid 34106916)
73. Kaneko, Y., F. Nimmerjahn, and J. V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670-673. (Pubitemid 44201145)
74. Malhotra, R., M. R. Wormald, P. M. Rudd, P. B. Fischer, R. A. Dwek, and R. B. Sim. 1995. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1:237-243.